Knowledge Hub
Categories:
- Allergy [1]
- Antimicrobials & infection [5]
- Autoimmune [1]
- Chemical Pathology [15]
- Endocrinology [1]
- Epidemiology [3]
- Gastrointestinal [2]
- Genetics [6]
- Genitourinary [2]
- Haematology [9]
- HIV/TB [3]
- Infectious Diseases [10]
- Neurology [4]
- Obstetric and Neonatal care [4]
- Oncology [1]
- Ophthalmology [1]
- Respiratory [2]
- Serology [3]
- Virology [44]
With regard to Designated Service Provider (DSP) Contracts the following law is pertinent for service providers who are not a DSP:
- In terms of Section 59 (2) of the Medical Schemes Act 131 of 1998 the medical scheme must pay valid invoices within 30 days of receipt thereof or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct the invoice.
- Where services are in respect of medical emergencies or involuntarily obtained services for PMB conditions, the scheme has to pay for the full cost of the services provided without deduction or co-payment or limiting the tariff amount. (Regulation 8 (1) of the Medical Schemes Act no. 131 of 1998.)
- DOH notice 214 of 2021 requires that a scheme pays for services provided at the same rate and in terms of the same rules as they pay their DSPs in respect of services voluntarily obtained, whether they are PMBs or not.
- The process followed in respect of appointing a DSP is required to be fair, equitable, transparent, competitive or cost effective as required in terms of Notice 214 of the DOH.
In summary:
- The law protects the patient’s choice to use their laboratory of choice, even if it is not a DSP, and the scheme is still obliged to reimburse us at the scheme rate for valid claims.
- This is true for PMB conditions as well as non-PMB conditions.
- The medical scheme must pay valid invoices within 30 days or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct invoice.
- A scheme must pay for the services provided at a tariff not less than what they would pay a DSP.
- Should any patient have a valid claim rejected because we are not a DSP, we can assist.
The ABC’s of MICs: The value of MIC results in antibiotic treatment decisions
The clinical microbiology laboratory provides valuable susceptibility data that can guide the selection of antibiotic regimens for patients with infections.
Xpert MTB/XDR Testing
PathCare introduces Xpert MTB/XDR testing as a reflex test for rapid molecular drug susceptibility testing of rifampicin-resistant Mycobacterium tuberculosis (RR-TB) positive clinical samples
Respiratory Pathogen Statistics July 2025
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during July 2025
Launch of Urine Free Metanephrines Testing via HRAM LC-MS – Effective 29 July 2025
We are pleased to announce an important enhancement to our endocrine diagnostics service.
Respiratory Pathogen Statistics June 2025
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare Laboratories during June 2025.
The Diabetes Management Report
PathCare has developed a unique reporting tool which consolidates pathology results for diabetic patients.
IS IT HYPERKALAEMIA OR PSEUDOHYPERKALAEMIA
Hyperkalaemia, defined as a potassium concentration greater than the reference interval, is a common electrolyte disorder that requires urgent attention.
Respiratory Pathogen Statistics May 2025
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during May 2025.
New Guideline: Oral Valaciclovir for the prevention of congenital CVM
Congenital cytomegalovirus (cCMV) infection carries a significant burden with a 0.64% global prevalence, while in resource-limited settings the prevalence may be in excess of 5%.